Status:
RECRUITING
Analysis of the Role of IgE Proteoforms in Health and Disease
Lead Sponsor:
KU Leuven
Conditions:
Anaphylaxis
Mastocytosis
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a ...
Eligibility Criteria
Inclusion Criteria:
- CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)
- Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)
Exclusion Criteria:
- Absence of informed consent
- Age < 18 years old
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07328178
Start Date
January 1 2025
End Date
January 1 2029
Last Update
January 9 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UZ/KU Leuven
Leuven, Vlaams-Brabant, Belgium, 3000